Cytokinetics, Incorporated (CYTK)
Cytokinetics, Incorporated (CYTK) Discusses ACACIA-HCM Topline Results From Pivotal Phase 3 Trial of Aficamten in Non-Obstructive HCM Transcript
Cytokinetics, Incorporated (CYTK) Discusses ACACIA-HCM Topline Results From Pivotal Phase 3 Trial of Aficamten in Non-Obstructive HCM Transcript
Can Myqorzo Drive Growth for Cytokinetics Amid Competition?
CYTK enters the commercial stage with FDA-approved Myqorzo for oHCM, eyeing strong market share, but faces stiff competition and execution risks.
Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?
Bridgefront Capital LLC Invests $572,000 in Cytokinetics, Incorporated $CYTK
Bridgefront Capital LLC purchased a new position in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 10,409 shares of the biopharmaceutical company's stock, valued at approximately $572,000. A number of other hedge funds
Cytokinetics Highlights Early MYQORZO Momentum, Eyes Q2 nHCM Phase 3 Catalyst at Barclays Confab
Cytokinetics (NASDAQ: CYTK) executives told investors at the Barclays healthcare conference that the company's U.S. launch of MYQORZO is still in its earliest phase but showing what management described as encouraging initial signs, while a key phase 3 readout in non-obstructive hypertrophic cardiomyopathy (nHCM) remains a major near-term catalyst. Early MYQORZO launch indicators Chief Executive Officer
Cytokinetics, Incorporated (CYTK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Cytokinetics, Incorporated (CYTK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans
CYTK reports a wider-than-expected Q4 loss as expenses rise, but Myqorzo wins FDA nod and global expansion advances, with $1.22B cash fueling 2026 catalysts.
Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript
Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript
Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) came out with a quarterly loss of $1.5 per share versus the Zacks Consensus Estimate of a loss of $1.48. This compares to a loss of $1.26 per share a year ago.
Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo
CYTK secures EU approval for Myqorzo in symptomatic obstructive HCM, expanding its first commercial drug across major global markets.
Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
